Search results for "FDA update"


 
Results 31 - 40 of about 57 for "FDA update".

New labels warn against sharing multi-dose insulin pens

In an effort to reduce the risk of infection spread, the FDA recently required additional label warnings about sharing of multi-dose diabetes pen devices, which are intended for single patient ... Insulin pens and pens for other injectable diabetes
March 2015

Warning on DPP-4 inhibitors and insulin recall

Dipeptidyl peptidase-4 (DPP-4) inhibitors may cause joint pain that can be severe and disabling, and some insulin pods may fail, the FDA recently warned. ... Dipeptidyl peptidase-4 (DPP-4) inhibitors may cause joint pain that can be severe and disabling,
September 2015

Saxagliptin under analysis for heart failure risk

The FDA has requested clinical trial data on saxagliptin (Onglyza and Kombiglyze XR) to investigate a possible increase in heart failure in patients taking the drug. ... The manufacturer is expected to submit the data to the FDA by early March 2014,
February 2014

Inhaled insulin approved

Afrezza, a rapid-acting, inhaled human insulin, was recently approved by the FDA to treat diabetes in adults. ... The most common adverse reactions in trials were hypoglycemia, cough, and throat pain or irritation, according to an FDA.
July 2014

FDA update

Certain models of the MiniMed insulin pump were recalled by Medtronic due to potential cybersecurity risks, the FDA warned on June 27. ... Because the manufacturer cannot update the MiniMed 508 and MiniMed Paradigm series insulin pump models, patients
July 2019

Abbot FreeStyle Insulinx meters recalled

The Abbott FreeStyle Insulinx blood glucose meters were recently recalled because at extremely high blood glucose levels of 1,024 mg/dL and above, the meters will display and store in memory an incorrect test result that is 1,024 mg/dL below the
July 2013

New warnings on medications containing saxagliptin, alogliptin

New warnings will be placed on saxagliptin and alogliptin about the potential risk of heart failure, particularly in patients with heart or kidney disease, the FDA announced on April 5. ... The FDA recommends that clinicians consider discontinuing
April 2016

Empagliflozin approved to treat type 2 diabetes

Empagliflozin (Jardiance), a sodium glucose co-transporter 2 inhibitor, was recently approved to treat type 2 diabetes in addition to diet and exercise, the FDA announced last week. ... The FDA is requiring 4 postmarketing studies to investigate
August 2014

New weight loss drug approved

Lorcaserin hydrochloride (Belviq) was recently approved by the FDA for chronic weight management in adults. ... Lorcaserin hydrochloride (Belviq) was recently approved by the FDA for chronic weight management in adults with a body mass index (BMI) of 30
September 2012

New drug approved, meters recalled

Dapaglifozin (Farxiga), a new medication to treat type 2 diabetes, was recently approved by the FDA for use along with diet and exercise. ... The FDA also announced a recall of some TRUEbalance and TRUEtrack blood glucose meters by Nipro Diagnostics, Inc.
March 2014

Result Page: Prev   1   2   3   4   5   6   Next